Plegridy (PEG-interferon β-1a) / Biogen  >>  Phase 4
Welcome,         Profile    Billing    Logout  

9 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Plegridy (PEG-interferon β-1a) / Biogen
BRITE, NCT02568111 / 2015-002159-89: Brimonidine Tartrate for the Treatment of Injection Related Erythema

Withdrawn
4
0
Europe
peginterferon beta-1a, PEGylated Interferon Beta-1a, PEG IFN β-1a, Plegridy, BIIB017, brimonidine tartrate, Mirvaso, Vehicle Gel
Biogen
Relapsing-Remitting Multiple Sclerosis (RRMS)
08/16
08/16
NCT02665221: Single Center, Open Label, Study of Preparation H on Erythema in Relapsing MS Patients Treated With PLEGRIDY

Terminated
4
30
US
No Treatment Arm, Topical Preparation H arm
NYU Langone Health
Multiple Sclerosis
09/16
09/16
Frequency, NCT02234869: Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy

Withdrawn
4
0
US
Interferon Beta, Rebif or Betaseron/Betaferon, BIIB017 (Peginterferon beta-1a), PEGylated interferon beta-1a (IFN β-1a)
Biogen
Relapsing Multiple Sclerosis
02/17
03/18
2017-002634-24: MultipleMS – a study with the aim to accelerate personalised medicine in multiple sclerosis. MultipleMS - en studie med syftet att utveckla precisionsmedicin för multipel skleros.

Ongoing
4
150
Europe
Infusion, Capsule, Tablet, Injection, Mabthera, Tysabri, Tecfidera, Gilenya, Copaxone, Betaferon, Extavia, Avonex, Rebif, Plegridy, Lemtrada, Aubagio
Karolinska Institutet, Department of Clinical Neuroscience, Karolinska Institutet
Newly diagnosed patients with Clinically Isolated Syndrome (CIS) and multiple sclerosis (MS) -both relapsing remitting and primary progressive), Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system (CNS), characterized by repeated episodes of inflammation in the CNS leading to various neurological symptoms., Diseases [C] - Nervous System Diseases [C10]
 
 
PLATINUM, NCT02587065 / 2015-002201-11: Plegridy Satisfaction Study in Participants

Completed
4
193
Europe
peginterferon beta-1a, BIIB017, PEGylated Interferon Beta-1a, Plegridy, PEG IFN β-1a
Biogen
Relapsing-Remitting Multiple Sclerosis (RRMS)
10/17
12/17
VITALITY, NCT03091569: Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy

Completed
4
23
Europe
Vitamin K Cream, Filloskin K1, Placebo Cream
Biogen
Relapsing-Remitting Multiple Sclerosis
01/18
01/18
NCT03424733: Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects

Unknown status
4
50
US
Plegridy, Pegylated Interferon beta-1a, Prednisone, Tylenol Pill, Acetaminophen
Holy Name Medical Center, Inc., Biogen
Multiple Sclerosis
05/20
05/20
PLENO, NCT03177083 / 2016-000434-21: Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy

Completed
4
80
Europe
peginterferon beta-1a, PLEGRIDY, BIIB017, interferon beta-1a, Rebif, interferon beta-1b, Betaferon, Extavia
Biogen
Relapsing Remitting Multiple Sclerosis
10/20
10/20
DELIVER-MS, NCT03535298: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

Active, not recruiting
4
800
Europe, US
Early Highly Effective Therapies Group, Lemtrada (alemtuzumab), Ocrevus (ocrelizumab), Tysabri (natalizumab), Rituxan (rituximab), Kesimpta (ofatumumab), Briumvi (ublituximab), Escalation Therapies Group, Betaseron (beta interferon), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Extavia (beta interferon), Gilenya (fingolimod), Glatopa (glatiramer acetate), Plegridy (beta interferon), Rebif (beta interferon), Tecfidera (dimethyl fumarate), Avonex (beta interferon), Mavenclad (cladribine), Mayzent (siponimod), Vumerity (diroximel fumarate), Zeposia (ozanimod), Bafiertam (monomethyl fumarate), Ponvory (ponesimod)
The Cleveland Clinic, University of Nottingham
Multiple Sclerosis, Relapsing-Remitting
07/27
09/30

Download Options